EWTX
EdgewiseยทNASDAQ
--
--(--)
--
--(--)
EWTX Profile
Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company which develops small molecule therapies for rare muscle diseases
1715 38th St., Boulder, CO 80301
--
Edgewise Therapeutics, Inc., was incorporated in Delaware in May 2017. The company is a science-driven biotechnology company focused on developing therapies for serious muscle diseases, with the initial target of rare neuromuscular and heart diseases. Its lead drug candidate sevasemten is an oral small molecule inhibitor that is in late-stage clinical development for the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
